Aptevo Therapeutics financials
$1.86−2.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$6.4M | -$6.8M | -$6.0M | -$7.6M | -$6.2M | -$6.5M | -$6.4M | -$5.2M | -$6.0M | -$7.0M | -$6.4M | -$6.6M |
| Net income | -$6.4M | -$6.7M | -$5.9M | -$9.0M | -$6.2M | -$6.4M | -$6.3M | -$5.1M | -$5.9M | -$6.8M | -$5.9M | -$6.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-5.31 | $-6.41 | — | $-40.14 | $-151.29 | $-1581.81 | $-2129.68 | $-6441.48 | $-22265.28 | $-132555.60 | $-71560.04 | $-295171.20 |
| EBITDA | -$6.4M | -$6.8M | -$5.9M | -$7.6M | -$6.2M | -$6.4M | -$6.3M | -$5.1M | -$5.9M | -$6.9M | -$6.3M | -$6.4M |
| Operating cash flow | -$5.5M | -$8.0M | -$5.2M | -$6.7M | -$7.1M | -$6.6M | -$5.8M | -$5.2M | -$6.2M | -$6.7M | -$5.3M | -$6.2M |
| Free cash flow | -$5.5M | -$8.0M | -$5.2M | -$6.7M | -$7.1M | -$6.6M | -$5.8M | -$5.2M | -$6.2M | -$6.7M | -$5.3M | -$6.2M |
| Diluted shares | 1.2M | 1.1M | — | 0.2M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.8M | $14.5M | $21.6M | $21.1M | $9.4M | $2.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $14.5M | $19.9M | $27.2M | $27.0M | $15.6M | $8.3M |
| Total liabilities | $8.5M | $8.3M | $9.8M | $9.6M | $9.1M | $9.8M |
| Shareholders' equity | $6.0M | $11.6M | $17.4M | $17.4M | $6.5M | -$1.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology